08:47 AM EDT, 07/11/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Friday that updated data from a phase 2 trial of its lead immunotherapy candidate Bria-IMT combined with an immune checkpoint inhibitor showed "meaningful" survival advantage over Gilead Sciences' ( GILD ) Trodelvy and single agent chemotherapy in metastatic breast cancer patients.

The company said the data showed median overall survival of 13.9 months in triple negative breast cancer patients receiving the Bria-IMT regimen, compared with 11.8 months for Trodelvy and 6.9 months for single-agent chemotherapy.

For hormone receptor positive patients, median overall survival was 17.3 months compared with 14.4 months for Trodelvy and 11.2 months for chemotherapy, BriaCell added.

BriaCell Chief Executive William Williams said they intend to validate these findings in their ongoing phase 3 trial with overall survival as primary endpoint.